Of note, recent studies highlighted the importance of a precise pharmacological regulation of mTOR activity in NSCs, since hyperactive mTOR is associated with Alzheimer's Disease both in patients and mouse models (Nicaise et al, 2020). The gene discussed is MTOR; the disease is early-onset autosomal dominant Alzheimer disease.